Cargando…
Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
OBJECTIVES: Evaluate the experiences and perceptions of patients participating in a simulated clinical trial and identify ways to enhance future patient-centric trial designs. DESIGN: International, multicentre, non-interventional, virtual clinical trial visits with patient debriefs and advisory boa...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151841/ https://www.ncbi.nlm.nih.gov/pubmed/37094891 http://dx.doi.org/10.1136/bmjopen-2022-064159 |
_version_ | 1785035628472172544 |
---|---|
author | Boisvert-Huneault, Christian Trigos Herraez, David Pinter, Andreas Kobayashi, Satomi Bell, Stacie Kallsen, Kimberley Gloede, Tristan Yagi, Nobutaka Brunette, Steven Datsenko, Yakov Baehner, Frank Clerisme-Beaty, Emmanuelle Van de Kerkhof, Peter |
author_facet | Boisvert-Huneault, Christian Trigos Herraez, David Pinter, Andreas Kobayashi, Satomi Bell, Stacie Kallsen, Kimberley Gloede, Tristan Yagi, Nobutaka Brunette, Steven Datsenko, Yakov Baehner, Frank Clerisme-Beaty, Emmanuelle Van de Kerkhof, Peter |
author_sort | Boisvert-Huneault, Christian |
collection | PubMed |
description | OBJECTIVES: Evaluate the experiences and perceptions of patients participating in a simulated clinical trial and identify ways to enhance future patient-centric trial designs. DESIGN: International, multicentre, non-interventional, virtual clinical trial visits with patient debriefs and advisory boards. SETTING: Virtual clinic visits and accompanying advisory boards. PARTICIPANTS: Nine patients with palmoplantar pustulosis for simulated trial visits; 14 patients and patient representatives for advisory boards. MAIN OUTCOME MEASURES: Qualitative responses to trial documentation, visit schedule and logistics, and trial design were collected during patient debriefs. Results were discussed at two virtual advisory board meetings. RESULTS: Patients identified key barriers to participation and potential difficulties encountered when attending trial visits and completing assessments. They also proposed recommendations to overcome these challenges. Patients recognised the need for comprehensive informed consent forms, but recommended use of non-technical language, brevity and additional support to aid understanding. Other trial documentations should be relevant to the disease and include known efficacy and safety of the study drug. Patients were concerned about receiving placebo, stopping existing medications and being unable to receive the study drug after trial completion; therefore, patients and physicians recommended an open-label extension following trial completion. Trial visits were too numerous (n=20) and too long (3–4 hours each); patients recommended improvements to the design to make best use of their time and reduce unnecessary waiting. They also requested financial and logistical support. Patients expressed a desire for study outcomes that matter to them, related to their ability to undertake normal daily activities and not be a burden to others. CONCLUSIONS: Simulated trials are an innovative method for assessing trial design and acceptance from a patient-centric perspective, enabling specific improvements to be made prior to trial initiation. Incorporation of recommendations from simulated trials could enhance trial recruitment and retention, and optimise trial outcomes and data quality. |
format | Online Article Text |
id | pubmed-10151841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-101518412023-05-03 Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study Boisvert-Huneault, Christian Trigos Herraez, David Pinter, Andreas Kobayashi, Satomi Bell, Stacie Kallsen, Kimberley Gloede, Tristan Yagi, Nobutaka Brunette, Steven Datsenko, Yakov Baehner, Frank Clerisme-Beaty, Emmanuelle Van de Kerkhof, Peter BMJ Open Dermatology OBJECTIVES: Evaluate the experiences and perceptions of patients participating in a simulated clinical trial and identify ways to enhance future patient-centric trial designs. DESIGN: International, multicentre, non-interventional, virtual clinical trial visits with patient debriefs and advisory boards. SETTING: Virtual clinic visits and accompanying advisory boards. PARTICIPANTS: Nine patients with palmoplantar pustulosis for simulated trial visits; 14 patients and patient representatives for advisory boards. MAIN OUTCOME MEASURES: Qualitative responses to trial documentation, visit schedule and logistics, and trial design were collected during patient debriefs. Results were discussed at two virtual advisory board meetings. RESULTS: Patients identified key barriers to participation and potential difficulties encountered when attending trial visits and completing assessments. They also proposed recommendations to overcome these challenges. Patients recognised the need for comprehensive informed consent forms, but recommended use of non-technical language, brevity and additional support to aid understanding. Other trial documentations should be relevant to the disease and include known efficacy and safety of the study drug. Patients were concerned about receiving placebo, stopping existing medications and being unable to receive the study drug after trial completion; therefore, patients and physicians recommended an open-label extension following trial completion. Trial visits were too numerous (n=20) and too long (3–4 hours each); patients recommended improvements to the design to make best use of their time and reduce unnecessary waiting. They also requested financial and logistical support. Patients expressed a desire for study outcomes that matter to them, related to their ability to undertake normal daily activities and not be a burden to others. CONCLUSIONS: Simulated trials are an innovative method for assessing trial design and acceptance from a patient-centric perspective, enabling specific improvements to be made prior to trial initiation. Incorporation of recommendations from simulated trials could enhance trial recruitment and retention, and optimise trial outcomes and data quality. BMJ Publishing Group 2023-04-24 /pmc/articles/PMC10151841/ /pubmed/37094891 http://dx.doi.org/10.1136/bmjopen-2022-064159 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Dermatology Boisvert-Huneault, Christian Trigos Herraez, David Pinter, Andreas Kobayashi, Satomi Bell, Stacie Kallsen, Kimberley Gloede, Tristan Yagi, Nobutaka Brunette, Steven Datsenko, Yakov Baehner, Frank Clerisme-Beaty, Emmanuelle Van de Kerkhof, Peter Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study |
title | Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study |
title_full | Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study |
title_fullStr | Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study |
title_full_unstemmed | Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study |
title_short | Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study |
title_sort | understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study |
topic | Dermatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151841/ https://www.ncbi.nlm.nih.gov/pubmed/37094891 http://dx.doi.org/10.1136/bmjopen-2022-064159 |
work_keys_str_mv | AT boisverthuneaultchristian understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy AT trigosherraezdavid understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy AT pinterandreas understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy AT kobayashisatomi understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy AT bellstacie understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy AT kallsenkimberley understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy AT gloedetristan understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy AT yaginobutaka understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy AT brunettesteven understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy AT datsenkoyakov understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy AT baehnerfrank understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy AT clerismebeatyemmanuelle understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy AT vandekerkhofpeter understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy |